Table 5. Results of the cost-effectiveness analysis.
Expected costs are those expected for a subject entering the treatment strategy arm, including all outcomes and complications in year 2002 USD. Effectiveness (survival) is expressed in quality-adjusted life years.
| Treatment Strategy |
Expected Cost (x$1000) |
Marginal Cost (x$1000) |
Survival (QALY) |
Marginal Survival (QALY) |
C/E Ratio | Incremental C/E Ratio (ICER) |
|---|---|---|---|---|---|---|
| No Transplant | 63 | - | 2.0 | - | $32,969 | - |
| Listed for DDLT | 150 | 87 | 4.4 | 2.4 | $34,648 | $35,976 |
|
Listed for DDLT
with LDLT available |
214 | 64 | 4.9 | 0.5 | $43,487 | $106,788 |